How many insider declarations has Feltquate David filed?

Feltquate David has filed 2 public insider declarations with SEC (Form 4).

What is Feltquate David's role?

Feltquate David's reported role is not specified by the regulator across the filings.

Which companies does Feltquate David report trades for?

Feltquate David reports trades for 2 companies, including iTeos Therapeutics, Inc..

← Executives ★ Sign in to follow

FD

Feltquate David

OFFICER

·SEC (Form 4)

iTeos Therapeutics, Inc.iTeos Therapeutics, Inc.

0

申报总数

0

公司

—

▲ 买入（0 笔）

—

▼ 卖出（0 笔）

内部人交易记录

其他

已披露买入

0

已披露卖出

0

尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。

信号历史

无可用的信号评分。

Discover the detailed record of transactions filed by Feltquate David. Director active across 2 companies, notably iTeos Therapeutics, Inc.. Aggregated, 2 filings have been recorded. Activity tracked since 6 December 2024. The latest transaction was disclosed on 6 December 2024 (Attribution). Regulator: SEC (Form 4). The full history is openly available.

Companies and markets linked to Feltquate David

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

iTeos Therapeutics, Inc. (US)iTeos Therapeutics, Inc. (US)

申报2 总计

●

Feltquate David

Chief Medical Officer高管2025年8月29日iTeos Therapeutics, Inc.

0SEC ↗

47,000 股Common StockSEC:0000950170-25-112238:0

◆

Feltquate David

Chief Medical Officer高管2024年12月6日iTeos Therapeutics, Inc.

0SEC ↗

47,000 股0Common StockSEC:0000950170-24-134239:0

2 条申报中的 2 条

InsidersTradesSigma

← Executives ★ Sign in to follow

FD

Feltquate David

OFFICER

·SEC (Form 4)

iTeos Therapeutics, Inc.iTeos Therapeutics, Inc.

0

申报总数

0

公司

—

▲ 买入（0 笔）

—

▼ 卖出（0 笔）

内部人交易记录

其他

已披露买入

0

已披露卖出

0

尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。

信号历史

无可用的信号评分。

Discover the detailed record of transactions filed by Feltquate David. Director active across 2 companies, notably iTeos Therapeutics, Inc.. Aggregated, 2 filings have been recorded. Activity tracked since 6 December 2024. The latest transaction was disclosed on 6 December 2024 (Attribution). Regulator: SEC (Form 4). The full history is openly available.